Our board

The Board of Directors is the company’s highest administrative body subordinate to the AGM. The work of Abliva’s Board of Directors is regulated by applicable laws and ordinances, and by the Board of Directors’ rules of procedure, which are adopted annually. The rules of procedure contain rules for dividing responsibilities between the Board of Directors and CEO, financial reporting and audit issues.

David Laskow-Pooley

Chairman (2017, elected 2016)

Born: 1954

Education: BSc Pharmacy (1st), Pharmaceutical/ Chemical engineering specialty and QP., Sunderland School of Pharmacy.

Other ongoing assignments: Director of the Board of Marker Therapeutics Inc. (England), Pharmafor Ltd, England, and LREsystem Ltd, (England).

No. of shares in Abliva: 45 828

Other: Non-affiliated to the Company, the management and to major owners.

David Bejker

Director (2017)

Born: 1975

Education: M.Sc. (Econ.), Stockholm School of Economics.

Other ongoing assignments: Director of the Board of LIDDS AB and Amylonix AB, CEO of Affibody Medical AB.

No. of shares in Abliva: 100 000

Other: Non-affiliated to the Company, the management and to major owners.

Roger Franklin

Director (2020)

Born: 1979

Education: M.Biochem (1st class), Molecular & Cellular Biochemistry, University of Oxford (UK), PhD, MRC Laboratory of Molecular Biology from University of Cambridge (UK).

Other ongoing assignments: Partner at Hadean Ventures, Director at Gesynta Pharma AB, Deputy Director at SAGA Diagnostics AB, and Board observer at Step Pharma SAS and Pipeline Therapeutics Inc.

No. of shares in Abliva:

Other: Non-affiliated to the company and the management, but not to major owners.

Denise Goode

Director (2018)

Born: 1958

Education: Institute of Chartered Accountants in England and Wales Chartered Accountant. B.Sc. Zoology from The University of Manchester (UK).

Other ongoing assignments: Director of the Board and CEO of QED Life Sciences Limited, Director of the Board of Dechra Pharmaceuticals PLC. and VP Business Development at AnaMar AB.

No. of shares in Abliva:

Other: Non-affiliated to the company, the management, and to major owners.

Jan Törnell

Director (2017)

Born: 1960

Education: MD and PhD in physiology, University of Gothenburg.

Other ongoing assignments: CEO and Director the Board of Innoext AB, Chairman of the Board of LIDDS AB and Glactone Pharma AB, Director of the Board of Diaprost AB, and Deputy Director of the Board of LIDDS Pharma AB.

No. of shares in Abliva: 45 828

Other: Non-affiliated to the Company, the management and to major owners.